Name:
Atanasov et al.pdf
Size:
1.669Mb
Format:
PDF
Description:
PMC Open Access Subset for ...
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2021-01-28
Metadata
Show full item recordAbstract
Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural products also present challenges for drug discovery, such as technical barriers to screening, isolation, characterization and optimization, which contributed to a decline in their pursuit by the pharmaceutical industry from the 1990s onwards. In recent years, several technological and scientific developments - including improved analytical tools, genome mining and engineering strategies, and microbial culturing advances - are addressing such challenges and opening up new opportunities. Consequently, interest in natural products as drug leads is being revitalized, particularly for tackling antimicrobial resistance. Here, we summarize recent technological developments that are enabling natural product-based drug discovery, highlight selected applications and discuss key opportunities.Citation
Nat Rev Drug Discov. 2021 Jan 28:1–17. doi: 10.1038/s41573-020-00114-z. Epub ahead of print.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.; HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
Springer NatureJournal
Nature reviews. Drug discoveryPubMed ID
33510482Type
ReviewLanguage
enEISSN
1474-1784ae974a485f413a2113503eed53cd6c53
10.1038/s41573-020-00114-z
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
- Authors: Ryan R, Hill S
- Issue date: 2019 Oct 23
- Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
- Authors: Kirtsoglou E, Simpson B, Salisbury L, Baraitser L
- Issue date: 2020
- Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.
- Authors: GBD 2021 US Burden of Disease and Forecasting Collaborators
- Issue date: 2024 Dec 7
- Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
- Authors: Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF
- Issue date: 2022 Oct
- Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
- Authors: Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH
- Issue date: 2024 Dec 1